Trial · NCT02600494
Adverse events80
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 80
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Somnolence | Nervous system disorders | Part A Lumateperone 28 mg (ITI-007 40 mg Tosylate) | 21 | 180 | |
| other | Somnolence | Nervous system disorders | Part A Lumateperone 42 mg (ITI-007 60 mg Tosylate) | 24 | 184 | |
| other | Somnolence | Nervous system disorders | Part A Placebo | 7 | 185 | |
| other | Somnolence | Nervous system disorders | Part B Lumateperone 42 mg (ITI-007 60 mg Tosylate) | 11 | 127 | |
| other | Headache | Nervous system disorders | Part A Lumateperone 28 mg (ITI-007 40 mg Tosylate) | 35 | 180 | |
| other | Headache | Nervous system disorders | Part A Lumateperone 42 mg (ITI-007 60 mg Tosylate) | 20 | 184 | |
| other | Headache | Nervous system disorders | Part A Placebo | 10 | 185 | |
| other | Headache | Nervous system disorders | Part B Lumateperone 42 mg (ITI-007 60 mg Tosylate) | 26 | 127 | |
| other | Nausea | Gastrointestinal disorders | Part A Lumateperone 28 mg (ITI-007 40 mg Tosylate) | 12 | 180 | |
| other | Nausea | Gastrointestinal disorders | Part A Lumateperone 42 mg (ITI-007 60 mg Tosylate) | 16 | 184 | |
| other | Nausea | Gastrointestinal disorders | Part A Placebo | 7 | 185 | |
| other | Nausea | Gastrointestinal disorders | Part B Lumateperone 42 mg (ITI-007 60 mg Tosylate) | 13 | 127 | |
| other | Dry Mouth | Gastrointestinal disorders | Part A Lumateperone 28 mg (ITI-007 40 mg Tosylate) | 13 | 180 | |
| other | Dry Mouth | Gastrointestinal disorders | Part A Lumateperone 42 mg (ITI-007 60 mg Tosylate) | 15 | 184 | |
| other | Dry Mouth | Gastrointestinal disorders | Part A Placebo | 3 | 185 | |
| other | Dry Mouth | Gastrointestinal disorders | Part B Lumateperone 42 mg (ITI-007 60 mg Tosylate) | 15 | 127 | |
| other | Dizziness | Nervous system disorders | Part A Lumateperone 28 mg (ITI-007 40 mg Tosylate) | 10 | 180 | |
| other | Dizziness | Nervous system disorders | Part A Lumateperone 42 mg (ITI-007 60 mg Tosylate) | 15 | 184 | |
| other | Dizziness | Nervous system disorders | Part A Placebo | 4 | 185 | |
| other | Dizziness | Nervous system disorders | Part B Lumateperone 42 mg (ITI-007 60 mg Tosylate) | 13 | 127 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02600494/events